Is DFTX or DMAC more undervalued in 2026?

CirclFi compares Definium Therapeutics, Inc. (DFTX) and DiaMedica Therapeutics Inc. (DMAC) using 13 institutional-grade valuation models. DFTX has a Quality of Company score of 4.8/10 while DMAC scores 4.7/10.

Which is a better buy — DFTX or DMAC?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do DFTX and DMAC valuations compare?

DFTX at $23.48 and DMAC at $6.16 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

DFTX vs DMAC Valuation Comparison 2026 — Intrinsic Value Analysis

DFTX

Biotechnology

Definium Therapeutics, Inc.

Quality

4.8

out of 10

Value Trap

SAFE

Price

$23.48

Last close

Models

10/13

Active

DMAC

Biotechnology

DiaMedica Therapeutics Inc.

Quality

4.7

out of 10

Value Trap

SAFE

Price

$6.16

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	DFTX Fair Value	DFTX Upside	DMAC Fair Value	DMAC Upside
Bayesian DCF	Intrinsic	$7.80	-66.8%	$1.70	-72.4%
Earnings Power Value	Intrinsic	$9.39	-58.2%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$1.50	-93.6%	$0.45	-92.7%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for DFTX vs DMAC — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

DFTX vs DMAC — Which Stock Is More Undervalued?

DFTX scores higher with a 4.8/10 quality rating vs DMAC's 4.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Definium Therapeutics, Inc. (DFTX) and DiaMedica Therapeutics Inc. (DMAC) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

DFTX currently trades at $23.48 with a QOC of 4.8/10, while DMAC trades at $6.16 with a QOC of 4.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).